• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

四种软件程序在实施决策分析成本效益模型中的比较。

A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models.

机构信息

Department of Emergency Medicine, University of Alberta, 3-264 Edmonton Clinic Health Academy, 11405 87 Ave NW, Edmonton, AB, T6G 1C9, Canada.

School of Public Health, University of Alberta, Edmonton, Canada.

出版信息

Pharmacoeconomics. 2017 Aug;35(8):817-830. doi: 10.1007/s40273-017-0510-8.

DOI:10.1007/s40273-017-0510-8
PMID:28488257
Abstract

The volume and technical complexity of both academic and commercial research using decision analytic modelling has increased rapidly over the last two decades. The range of software programs used for their implementation has also increased, but it remains true that a small number of programs account for the vast majority of cost-effectiveness modelling work. We report a comparison of four software programs: TreeAge Pro, Microsoft Excel, R and MATLAB. Our focus is on software commonly used for building Markov models and decision trees to conduct cohort simulations, given their predominance in the published literature around cost-effectiveness modelling. Our comparison uses three qualitative criteria as proposed by Eddy et al.: "transparency and validation", "learning curve" and "capability". In addition, we introduce the quantitative criterion of processing speed. We also consider the cost of each program to academic users and commercial users. We rank the programs based on each of these criteria. We find that, whilst Microsoft Excel and TreeAge Pro are good programs for educational purposes and for producing the types of analyses typically required by health technology assessment agencies, the efficiency and transparency advantages of programming languages such as MATLAB and R become increasingly valuable when more complex analyses are required.

摘要

在过去的二十年中,使用决策分析模型进行学术和商业研究的数量和技术复杂性迅速增加。用于实施这些模型的软件程序的范围也有所增加,但实际上,少数程序占据了绝大多数成本效益建模工作。我们报告了对四个软件程序的比较:TreeAge Pro、Microsoft Excel、R 和 MATLAB。我们的重点是常用于构建 Markov 模型和决策树以进行队列模拟的软件,因为它们在成本效益建模的已发表文献中占主导地位。我们的比较使用 Eddy 等人提出的三个定性标准:“透明度和验证”、“学习曲线”和“能力”。此外,我们引入了处理速度的定量标准。我们还考虑了每个程序对学术用户和商业用户的成本。我们根据这些标准对程序进行排名。我们发现,虽然 Microsoft Excel 和 TreeAge Pro 是用于教育目的和制作健康技术评估机构通常需要的类型分析的好程序,但当需要更复杂的分析时,编程语言(如 MATLAB 和 R)的效率和透明度优势变得越来越有价值。

相似文献

1
A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models.四种软件程序在实施决策分析成本效益模型中的比较。
Pharmacoeconomics. 2017 Aug;35(8):817-830. doi: 10.1007/s40273-017-0510-8.
2
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.避免和识别健康技术评估模型中的错误:定性研究和方法学综述。
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
3
R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study.用于成本效益分析的R语言和Shiny:为何以及何时使用?一个假设案例研究。
Pharmacoeconomics. 2020 Jul;38(7):765-776. doi: 10.1007/s40273-020-00903-9.
4
R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment.R 还在用 Excel 吗?健康技术评估现代化软件工具的优势。
Value Health. 2019 May;22(5):575-579. doi: 10.1016/j.jval.2019.01.003.
5
[Decision analytic modeling and their impact on health care decision making].[决策分析模型及其对医疗保健决策的影响]
Acta Pharm Hung. 2009;79(2):63-9.
6
Comparing three software tools for implementing markov models for health economic evaluations.比较三种用于实施健康经济评价马尔可夫模型的软件工具。
Pharmacoeconomics. 2009;27(9):745-53. doi: 10.2165/11313760-000000000-00000.
7
Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.卫生经济评估决策分析模型的验证:概述
Pharmacoeconomics. 2017 Jul;35(7):673-683. doi: 10.1007/s40273-017-0508-2.
8
An introduction to the methods of cost-effectiveness analysis.成本效益分析方法介绍。
Drug Ther Bull. 2012 Jul;50(7):81-4. doi: 10.1136/dtb.2012.06.0118.
9
Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code.验证 DICE 仿真与完全用代码实现的离散事件仿真的一致性。
Pharmacoeconomics. 2017 Oct;35(10):1103-1109. doi: 10.1007/s40273-017-0534-0.
10
Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms.脾动脉瘤血管内修复、开放修复及保守治疗的成本效益分析
J Vasc Surg. 2015 Jun;61(6):1432-40. doi: 10.1016/j.jvs.2014.12.064. Epub 2015 Mar 28.

引用本文的文献

1
Productivity Losses Due to Long-Term Back Problems in Working-Age Australians.澳大利亚工作年龄人群长期背部问题导致的生产力损失
JAMA Netw Open. 2025 Aug 1;8(8):e2527284. doi: 10.1001/jamanetworkopen.2025.27284.
2
Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews.采用生命周期卫生技术评估:基于公开报销审查的肿瘤agnostic精准肿瘤学指数经济评估
Int J Technol Assess Health Care. 2025 Jun 24;41(1):e41. doi: 10.1017/S0266462325100111.
3
Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results.

本文引用的文献

1
An Overview of R in Health Decision Sciences.健康决策科学中的 R 概述。
Med Decis Making. 2017 Oct;37(7):735-746. doi: 10.1177/0272989X16686559. Epub 2017 Jan 6.
2
Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach.从概率敏感性分析样本中估计完美信息的多参数部分预期值:一种非参数回归方法。
Med Decis Making. 2014 Apr;34(3):311-26. doi: 10.1177/0272989X13505910. Epub 2013 Nov 18.
3
Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
使用 R 进行健康技术评估中的决策分析建模的障碍和促进因素:焦点小组结果。
Pharmacoeconomics. 2024 Jul;42(7):783-795. doi: 10.1007/s40273-024-01374-y. Epub 2024 Apr 12.
4
Decision analysis in cardiac surgery: a scoping review and methodological primer.心脏外科学中的决策分析:范围综述和方法学入门。
Eur J Cardiothorac Surg. 2024 Mar 29;65(4). doi: 10.1093/ejcts/ezae123.
5
The cost-utility of intraoperative tranexamic acid in adult spinal deformity patients undergoing long posterior spinal fusion.术中氨甲环酸在接受长节段后路脊柱融合术的成人脊柱畸形患者中的成本效用。
Spine Deform. 2024 May;12(3):587-593. doi: 10.1007/s43390-023-00818-3. Epub 2024 Mar 1.
6
Community-based transport system in Shinyanga, Tanzania: A local innovation averting delays to access health care for maternal emergencies.坦桑尼亚欣扬加基于社区的交通系统:一项避免孕产妇紧急情况就医延误的本土创新。
PLOS Glob Public Health. 2023 Aug 2;3(8):e0001487. doi: 10.1371/journal.pgph.0001487. eCollection 2023.
7
Sentinel lymph node biopsy for head and neck cutaneous squamous cell carcinoma using the Brigham and Women's staging system: a cost analysis.采用布莱根妇女医院分期系统对头颈部皮肤鳞状细胞癌进行前哨淋巴结活检:一项成本分析。
Arch Dermatol Res. 2023 Apr;315(3):371-378. doi: 10.1007/s00403-022-02347-x. Epub 2022 Mar 18.
8
Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.卡瑞利珠单抗在中国晚期或转移性食管鳞状细胞癌二线治疗中的成本效益分析。
Ann Transl Med. 2021 Aug;9(15):1226. doi: 10.21037/atm-21-1803.
9
Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy.决策分析模型作为一种工具,用于为合并造血干细胞移植的血液系统恶性肿瘤患者选择最佳治疗方案。
Bone Marrow Transplant. 2020 Jul;55(7):1220-1228. doi: 10.1038/s41409-020-0784-x. Epub 2020 Jan 13.
10
One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit.单向灵敏度分析在概率性成本效果分析中的应用:条件期望增量净收益。
Pharmacoeconomics. 2020 Feb;38(2):135-141. doi: 10.1007/s40273-019-00869-3.
21 基因检测在指导早期乳腺癌辅助化疗决策中的成本效益。
Value Health. 2013 Jul-Aug;16(5):729-39. doi: 10.1016/j.jval.2013.03.1625. Epub 2013 Jul 1.
4
Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information.需要速度:一种计算部分完全信息单参数期望值的高效算法。
Value Health. 2013 Mar-Apr;16(2):438-48. doi: 10.1016/j.jval.2012.10.018. Epub 2013 Jan 26.
5
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.模型透明度和验证:ISPOR-SMDM 建模良好实践工作组报告-7。
Med Decis Making. 2012 Sep-Oct;32(5):733-43. doi: 10.1177/0272989X12454579.
6
Comparing three software tools for implementing markov models for health economic evaluations.比较三种用于实施健康经济评价马尔可夫模型的软件工具。
Pharmacoeconomics. 2009;27(9):745-53. doi: 10.2165/11313760-000000000-00000.
7
Expected value of sample information calculations in medical decision modeling.医学决策建模中样本信息计算的期望值
Med Decis Making. 2004 Mar-Apr;24(2):207-27. doi: 10.1177/0272989X04263162.